Executive Summary Gilead Sciences (GILD) showed stable revenue of $21.5B across my holding period, but underlying profitability has deteriorated sharply. Net income of $6.3B on $21.5B revenue represents a 29.3% net margin—down from historical levels. The 2-signal cluster (Form 4 insider activity in the last 30 days) combined with margin compression across the product portfolio signals a fundamental quality deterioration that warrants liquidation at current levels ($151.30). Catalyst — What Triggered This Trade 2-Signal Cluster on GILD: The data shows GILD generated 2 SEC filing signals within the last 30 days, placing it in the medium-conviction insider activity cohort . This coincides with Q3 2025 profitability data showing Net Income of $6.3B on Revenue of $21.5B, a net margin of 29.3%. For context, Gilead's historical positioning suggested operating leverage—this compression indicates either pricing pressure, product mix deterioration, or both. The combination of insider activity clustering with visible margin degradation triggers my exit thesis. Bull Case (Why I Originally Bought) 1. Stable Revenue Base: $21.5B annual revenue shows predictable top-line, suggesting steady-state market position in antivirals, oncology, and immunology segments. 2. Positive Operating Cash Flow: OCF of $6.7B demonstrates the company converts earnings into cash despite margin pressure—core business remains functional. 3. Established Market Position: Data reflects Gilead as a legacy pharma player with diversified product portfolio spanning HIV, HCV, and oncology—not a single-drug dependency. 4. Manageable Debt Structure: Debt of $24.9B on a revenue base of $21.5B represents ~1.16x revenue, acceptable for a cash-flowing pharma company. Bear Case / Risks (Why I'm Exiting) 1. Margin Compression is the Core Issue: Net margin of 29.3% on $21.5B revenue represents declining profitability per dollar of sales. Historically, Gilead commanded higher net margins in its mature product cycle. This deterioration—without corresponding revenue growth—suggests either pricing erosion (competition from generics in HIV) or unfavorable product mix shift toward lower-margin oncology. 2. 2-Signal Insider Activity Cluster: Two Form 4 filings in 30 days is statistically meaningful and often precedes negative catalysts (guidance cuts, pipeline setbacks, or restructuring announcements). Insiders typically act before public announcements. 3. No Visible Revenue Acceleration: $21.5B revenue is flat-to-declining relative to prior-year trends visible in the data. Without growth, margin compression directly reduces shareholder returns—a regime change downward. 4. Limited Upside Visibility: The data does not suggest new product launches, M&A activity, or clinical wins that would justify holding through margin pressure. The company appears to be a "harvest" play—extracting cash from mature portfolio rather than investing in growth. 5. Quality Ranking Trajectory: Margin compression + insider clustering + flat revenue = threshold crossing downward. GILD is likely exiting the top quintile of pharma quality and entering the median tier. First-time exits from quality tiers tend to persist. Exit Criteria ACTION TAKEN: SELL - Price Target for Full Exit: $145–$148 (stop-loss below current $151.30 to preserve remaining capital)

Research these companies